摘要
目的探讨对铜绿假单胞菌(PA)感染患者行药学干预的临床疗效及安全性。方法选取医院2015年8月至2017年5月收治的PA感染患者84例,依据初始给药方案有无优化(采用头孢他啶联合阿米卡星治疗少于3次/日)来确定是否进行干预,观察组(44例)为已经优化或接受干预患者,对照组(40例)为拒绝干预患者;记录两组患者治疗前的临床资料及病情分布情况。结果观察组患者的疗程、住院时间、体温恢复时间均短于对照组,治疗好转例数及细菌清除率均高于对照组(P<0.05);治疗3 d后,两组患者白细胞(WBC)、中性粒细胞(NEUT)恢复正常比例差异无统计学意义(P>0.05),治疗7 d后,观察组患者WBC和NEUT恢复正常比例高于对照组(P<0.05);治疗过程中,观察组有1例、对照组有2例患者因使用头孢哌酮舒巴坦而出现轻度过敏反应,临床表现为全身性皮疹,及时停药并进行抗过敏治疗后均明显好转。结论对PA感染患者进行给药方案干预,可明显提升临床疗效,且安全性较好,值得临床推广。
Objective To investigate the clinical efficacy and safety of pharmaceutical intervention on Pseudomonas aeruginosa(PA)infection.Methods Totally 84 patients with PA infection admitted to our hospital from August 2015 to May 2017 were selected,whether the intervention was played or not according to whether the initial dosing regimen was optimized or not(with ceftazidime combined with amikacin therapy less than 3 times/day).The observation group(44 cases) had been optimized or accepted the intervention,and the control group(40 cases) was refused intervention.The clinical data and the distribution of the disease before and after treatment were recorded in the two groups.Results The course of treatment,hospitalization time and recovery time of body temperature of the observation group were lower than those of the control group,and the cases of improved patients and bacterial clearance rate were higher than those of the control group(P < 0.05).After 3 d of treatment,the proportion of WBC and NEUT returned to normal in the two groups was not statistically significant(P > 0.05).After 7 d of treatment,the proportion of WBC and NEUT returned to normal in the observation group was higher than that in the control group(P < 0.05).In the treatment,there were 1 case with mild allergic reactions due to the use of cefoperazone sulbactam in the observation group,and 2 cases in the control group,the clinical manifestation was systemic rash,and the symptoms were obviously improved after the drug withdrawal and giving anti-allergy treatment in time.Conclusion The intervention of PA infection can significantly improve the clinical efficacy,and has good safety,which is worthy of clinical promotion.
作者
曾菁
肖瑶
奉川程
周理国
Zeng Jing;Xiao Yao;Feng Chuancheng;Zhou Liguo(Chongqing Qijiang People’s Hospital, Chongqing, China 401420)
出处
《中国药业》
CAS
2017年第22期86-88,共3页
China Pharmaceuticals
关键词
头孢他啶
阿米卡星
铜绿假单胞菌感染
药学干预
临床疗效
ceftazidime
amikacin
Pseudomonas aeruginosa infection
pharmaceutical intervention
clinical effect
